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MDDiffusionWeighted Imaging is extremely important for the diagnosis of probable sporadic Jakob–Creutzfeldt dis-
ease, themost common human prion disease. Although visual assessment of DWIMRI is critical diagnostically, a
more objective, quantiﬁable approach might more precisely identify the precise pattern of brain involvement.
Furthermore, a quantitative, systematic tracking of MRI changes occurring over time might provide insights
regarding the underlying histopathological mechanisms of human prion disease and provide information useful
for clinical trials. The purposes of this study were: 1) to describe quantitatively the average cross-sectional
pattern of reduced mean diffusivity, fractional anisotropy, atrophy and T1 relaxation in the gray matter (GM)
in sporadic Jakob–Creutzfeldt disease, 2) to study changes in mean diffusivity and atrophy over time and 3) to
explore their relationship with clinical scales. Twenty-six sporadic Jakob–Creutzfeldt disease and nine control
subjects hadMRIs on the same scanner; seven sCJD subjects had a second scan after approximately twomonths.
Cortical and subcortical graymatter regionswere parcellatedwith Freesurfer. Average cortical thickness (or sub-
cortical volume), T1-relaxiation and mean diffusivity from co-registered diffusion maps were calculated in each
region for each subject. Quantitatively on cross-sectional analysis, certain brain regions were preferentially
affected by reduced mean diffusivity (parietal, temporal lobes, posterior cingulate, thalamus and deep nuclei),
but with relative sparing of the frontal and occipital lobes. Serial imaging, surprisingly showed that mean diffu-
sivity did not have a linear or unidirectional reduction over time, but tended to decrease initially and then reverseK23AG021989, P50AG023501,NIH/NCRRGrantNumberUL1 RR024131, NIH/NIAAG021601, andNIH/NINDSContractN01-NS-
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427E. Caverzasi et al. / NeuroImage: Clinical 4 (2014) 426–435and increase towards normalization. Furthermore, there was a strong correlation between worsening of patient
clinical function (based on modiﬁed Barthel score) and increasing mean diffusivity.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Sporadic Jakob–Creutzfeldt disease (sCJD) is unique among neuro-
degenerative diseases as there is an MRI marker (restricted diffusion
of certain graymatter regions) with very high sensitivity and speciﬁcity
(Meissner et al., 2009; Vitali et al., 2011; Young et al., 2005). Most prior
MRI studies in sCJD studying cortical restricted diffusion have been
performedby a visual assessment analysis onﬂuid-attenuated inversion
recovery (FLAIR) and/or diffusion weighted images (DWI) sequences
(Meissner et al., 2009; Tschampa et al., 2007; Vitali et al., 2011; Young
et al., 2005). Due to MRI susceptibility and other artifacts, this “qualita-
tive” approach, however,may not show the extent of true brain involve-
ment (Lin et al., 2006). Improved understanding of the quantiﬁcation
and pattern of brain MRI changes that occur in sCJD (such as atrophy
and diffusion) (Cohen et al., 2009; Lee et al., 2012; Wang et al., 2013)
as well as their changes over time might provide important biomarker
data to track for future clinical trials, as well as provide insights on
mechanisms of the disease and prion spread. Tracking MRI progression
in other neurodegenerative diseases has usually been done by following
structural measures of white or gray matter integrity or metabolism;
such studies have consistently reported a roughly linear or unidirection-
al decline (Driscoll et al., 2009; Shiga et al., 2004). Additionally, it is
not clear what happens with restricted diffusion over time in sCJD
(Geschwind et al., 2009; White et al., 2003). To our knowledge, there
have been no formal studies on the course of DWI overtime in human
prion disease, only case reports. Some case reports suggest increasing
DWI involvement (Kono et al., 2011; Ukisu et al., 2005), whereas others
suggest less DWI involvement, particularly with atrophy (Matoba et al.,
2001; Tribl et al., 2002).
Although diffusion tensor imaging (DTI) has emerged as a sensitive
diagnostic technique highlighting mean diffusivity (MD) abnormalities
in the graymatter (GM) in humanprion diseases, few studies quantiﬁed
MD and fractional anisotropy (FA) abnormalities and none have exam-
ined regional and whole brain MD and FA both cross-sectionally and
longitudinally in a cohort of sCJD patients (Andrews, 2010; Fulbright
et al., 2006; Manners et al., 2009; Ukisu et al., 2005; Wang et al.,
2013). Our aims were 1) to describe quantitatively the average pattern
of reducedMD, FA, atrophy and T1 relaxation in the graymatter (GM) in
sCJD as well as 2) to determine the changes of mean diffusivity and
atrophy over time and 3) their relationship with clinical scales in a
sub-cohort with serial imaging.
2. Material and methods
2.1. Subjects
All subjects or their designees provided informed consent for partici-
pation in this study, which was approved by our institutional review
board. Subjects were evaluated between August 2005 and August
2008 at the University of California of San Francisco (UCSF) Memory
and Aging Center. We analyzed all serial sCJD subjects who had the
same MRI protocol of adequate quality MRI (n = 26; mean age 62,
SD ±9; 46% female). Twenty-three of 26 sCJD subjects (88%) had brain
autopsy and were ultimately pathologically-proven sCJD (Table 1)
(Kretzschmar et al., 1996); the three other subjects eventually met
UCSF 2007 (Geschwind et al., 2007) and either WHO, 1998 or European
probable sCJD criteria (WHO, 1998; Zerr et al., 2009). MRIs from nine
healthy age and gender matched subjects were used as controls (mean
age 62 (SD ±16) 44% female). Seven sCJD subjects had a second, serial
brain MRI after about two months (2.17, SD ±0.23 months).All sCJD subjects had a Mini-Mental State examination (MMSE), the
modiﬁed Barthel index, theNeuropsychiatric Inventory total score (NPI;
to assess the behavioral impairments) (Cummings, 1997) and detailed
standardized neurological examination (±3 days from MRI scan date)
(See Supplemental data and Table 1). For cases with pathology, prion
typing was performed by the National Prion Disease Pathology
Surveillance Center (NPDPSC; Cleveland, OH). Prion gene, PRNP, analy-
sis for mutations and codon 129 polymorphisms done through the
NPDPSC. All but one sCJD subjects were tested for PRNP mutations;
this subject was not pathologically-proven, but had no family history
of neuropsychiatric disorder and presented clinically as sCJD.
2.2. Imaging acquisition
Imageswere acquired on a 1.5 TGE Signa scanner. The acquisition pro-
tocol consisted in two axial T1-weighted 3D IRSPGR (axial slab with 60
slices of 3 mm thickness, TR/TE = 27/6 ms, in-plane matrix 256 × 256
covering a FOV of 24 × 24 cm2 ﬂip angle 40° and 8°), an axial T2 FLAIR
(48 slices of 3 mm thickness, TR/TE/TI = 8802/122/2200 ms, 512 × 512
matrix with a FOV of 24 × 24 cm2), and a DTI acquisition (15 non-
collinear gradient directions with b = 1000 s/mm2, one b = 0 reference
image, 35 contiguous slices of 3 mm thickness, TR/TE = 12,400/69 ms,
128 × 128 matrix covering a FOV of 25.6 × 25.6 interpolated to give a
ﬁnal 1 × 1 × 3mm3 resolution). Due to acquisitionwindowing problems,
information on the inferior temporal lobe (entorhinal, fusiform,
inferiotemporal, middletemporal, temporal pole ROIs) was lost for three
subjects.
2.3. Imaging analysis
The two T1-weighted 3-D inversion recovery-spoiled images (40
and 8°) were used to calculate the T1 relaxometry maps (T1R).
FreeSurfer Image Analysis Suite 4.5 version (http://surfer.nmr.mgh.
harvard.edu/) (Dale et al., 1999; Fischl et al., 1999) was used for cortical
reconstruction, volumetric segmentation, subcortical (Fischl et al.,
2004) and cortical parcellation (Desikan-Kyliany Atlas: 40 VOIs per
hemispherewith Freesurfer Atlas), aswell as determining cortical thick-
ness in each VOI and deep nuclei volumes. Volumes were normalized
for intracranial volume (Desikan et al., 2006). Segmentation results
were assessed by an experienced operator to ensure accuracy.
Mean diffusivity and fractional anisotropy (FA) maps were calculated
after eddy current and head motion correction. DTI data were corrected
by applying an afﬁne alignment of each image to the ﬁrst no diffusion
weighted (b0) image using the Oxford FSL toolkit (http://www.fmrib.oc.
ac.uk/fsl/fdt/index.html). DTI maps were registered to the T1-weighted
images. To decrease the potential effect of partial volume averaging, the
Freesurfer mask of CSF was applied to exclude voxels that were likely to
contain a mixture of CSF with GM from the VOI boundary. Averages
were calculated for MD, FA, T1R, and thickness or volume for each VOI.
2.4. Statistical analysis
2.4.1. Cross-sectional analysis
Age-corrected Z-scores were used in the Mann–Whitney U test to
compare the differences between the subjects and controls for MD, FA,
T1R, cortical thickness and subcortical volumes (volumes corrected for
intracranial volume). The Spearman non-parametric test was used to
assess the correlation between the diffusion and volumetric parameters
and the clinical data of the patients, as well as correlation test between
MD and thickness Z-scores. False discovery rate (FDR) adjustment was
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428 E. Caverzasi et al. / NeuroImage: Clinical 4 (2014) 426–435applied to correct formultiple comparisons. Differences in the degree of
pathology measured by MD were examined across molecular subtype
groups in terms of prion type and codon 129. Speciﬁcally, logistic
regression analyses were performed to investigate differences in MD
Z-scores across groups at the lobar level based on prion type or codon
129 polymorphism; smaller ROIs were not evaluated due to concern
for reduced statistical power. Both main effects of MD Z-scores and
effects of MD Z-Scores adjusted for modiﬁed Barthel Scores were exam-
ined; the latter to adjust for potential confounding due to differences in
the disease stage. These effects are reported in terms of t-statistic values
corresponding to Odds Ratio estimates.2.4.2. Longitudinal analysis
The nonparametric Wilcoxon signed rank test was used to evaluate
differences between the ﬁrst and second time MRI points, with FDR
adjustment to correct for multiple comparisons. The nonparametric
Wilcoxon rank sum test was used to compare clinical scale scores and
time periods between the seven serial subjects and the 19 subjects
with a single scan.
Spearman correlation coefﬁcients were used to assess the correla-
tion between the longitudinal changes (“delta scores”) of either MD,
FA or thickness/volume vs. delta scores of clinical scales (e.g., MMSE,
Barthel and NPI). FDR adjustmentwas used to correct for multiple com-
parisons only for VOIs; for lobar or hemispheric analyses no correction
was performed.2.4.3. Cross-sectional and longitudinal smoothing splines
Smoothing Splines were applied to examine non-linearities in
the following two relationships: a) cross-sectional average GM MD or
thickness/volume vs. Barthel scores; b) two-month changes in GM MD
vs. Barthel score at the baseline. Smoothing Splineswere applied to inves-
tigate an average tendency among behaviors of thewhole brain; occipital,
frontal, temporal, parietal lobes, limbic structure. Accuracy an estimate of
the average tendency is examined based on 1000 bootstrap samples and
presented using 95% conﬁdence intervals. The analysis was performed
using R Package for Scientiﬁc Computing (Efron and Tibshirani, 1993;
Green and Silverman, 1994; R Core Team, 2013).3. Results
The distribution of our codon 129 polymorphism subtypes in our
cohort was somewhat different than that expected for an sCJD popula-
tion (Chi-Square, P b 0.001), with both MV and VV over-represented
and fewer MM than expected (Table e1) (Alperovitch et al., 1999). We
could not compare the distribution of our full molecular subtypes to
those expected for sCJD (Parchi et al., 1999) as they have not yet been
established for Type 1/2 (Cali et al., 2009), whichwe had in our popula-
tion. The cohort was moderately advanced cognitively with a median
MMSE of 16/30, but only mildly functionally impaired with a median
Barthel of 78/100 (Table 1).3.1. Cross-sectional analysis
3.1.1. Cortical GM DTI metrics
With FDR, there was statistically signiﬁcant MD reduction in several
VOIs of parietal, temporal and occipital lobes, whereas in the frontal and
limbic lobes only in the right medial orbitofrontal (frontal), and bilater-
ally in the isthmus cingulate and right posterior cingulate (limbic)
(Table 2; Fig. 1). There also was a more widespread trend towards
reduction of averageMD in the cortical GMof sCJD compared to controls
particularly within frontal lobes (Fig. 1). No increased diffusion was
identiﬁed in any sCJD VOI. Sporadic CJD patients did not show any
statistical signiﬁcant FA change compared to controls.
429E. Caverzasi et al. / NeuroImage: Clinical 4 (2014) 426–4353.1.2. Subcortical GM DTI metrics
With FDR, there was statistically signiﬁcant MD reduction in the
sCJD group compared to controls bilaterally in the caudate, putamen,
thalamus, and pallidum and left amygdala (Table 2; Fig. 1). The right
amygdala showed only a trend towardsMD reduction (Fig. 1). Sporadic
CJD patients did not show any statistical signiﬁcant FA change com-
pared to controls.
3.1.3. Comparison of GM lobar MD ﬁndings based on prion type or codon
129 polymorphism
The average lobarMDwas signiﬁcantly lower in subjects with type 1
compared to type 2 PrPSc bilaterally in the occipital and parietal lobes,
and in the right limbic and right temporal lobes (p b0.05). There were
an insufﬁcient number of subjects to analyze further by complete
molecular subtype (Parchi et al., 1999) or by those with types 1 and 2
PrPSc (Cali et al., 2009). There were no differences in average lobar MD
by codon 129 polymorphism. Using regression analysis accounting for
Barthel scores, conﬁrmed themain effect of the prion type onMDdiffer-
ences (average MD in type 1 b type 2), speciﬁcally bilaterally in the
parietal (left p = 0.048, t = 1.8; right p = 0.02, t = 1.3) and occipital
lobes (left p = 0.04 t = 1.8; right p = 0.01, t = 2.4) and in the right
limbic (p = 0.02, t = 2.2) and right temporal (p = 0.03, t = 2), lobes.
Correcting for Barthel score in a regression analysis showed an effect
of the codon 129 polymorphism (MM, MV, and VV) on MD. MM cases
had reduced average MD than VV cases in left temporal (p = 0.02,
t = 2.08) lobe, whereas VV cases had reduced average MD in the
deep nuclei (left p = 0.03, t =−2.0; right p = 0.04, t =−1.8).
3.1.4. Cortical GM subcortical GM thickness/volume and T1R
With FDR, there were no statistically signiﬁcant differences in
cortical thickness or volume in the sCJD group compared to controls.
In the Supplemental data, we report the results without FDR correction
(Supplemental data). No statistically signiﬁcant T1R value differences
were found between sCJD and controls in any VOIs, including the globus
pallidus (GP), either with or without FDR (not shown).
3.1.5. Correlations between gray matter values and clinical scales and
times/duration
There were no signiﬁcant correlations, or even trends, between clin-
ical scales and cross-sectional GM MD values, GM thickness/volume in
any VOI, lobar and whole brain based analysis (not shown). There was
no correlation, or even trends, of MD values with thickness or volumes
in any of the cortical or subcortical GM VOIs, lobar and whole brain
based analysis (not shown). No correlations or trends were found
between GM MD or GM thickness (or volume) values in any VOI,
lobar andwhole brain based analysis with time toMRI, the total disease
duration or the MRI/duration ratio (not shown).
3.2. Longitudinal analysis
The subset of seven subjects analyzed longitudinally (1 MV2, 3
MM2, 1 MM1, 1 MM 1/2 and 1 MM N/A) did not differ signiﬁcantly
(nonparametric Wilcoxon rank sum test) in MMSE (p = 0.6), NPI
(p = 0.45) disease duration (p = 0.24), and time to MRI (p = 0.86)
from the 19 subjects with MRI at a single time point. The disease ratio
(time to ﬁrst MRI/disease duration), however, was statistically signiﬁ-
cant smaller in the seven longitudinal than in the 19 subjects with a
single MRI (cross-sectional only) (0.51 +/− 1.7 versus 0.74 +/− 1.5;
p = 0.007 z =−2.7), suggesting that the seven serial subjects were
temporally earlier in their disease course. The modiﬁed Barthel
(p = 0.15) trended towards being worse in the 19 cross-sectional
only subjects. Curiously, the four patients with high baseline Barthels
(100–80) had a much smaller mean decline in Barthel (Mean
−1.25+/− 2.5 SD) compared to the three patientswith lower baseline
Barthels (range, 75–35) who had a greater average decline in Barthel
(Mean−20 +/− 13 SD) over the two month interval.3.2.1. Delta GM DTI metrics and relationship with delta clinical scales
Over approximately two-months, in seven serial sCJD subjects, most
VOIs had increasing average MD from baseline, although a few VOIs
continued to show reducing MD from baseline; none of these serial
changes, however, were statistically signiﬁcant, either with or without
FDR (Supplemental Fig. 1). There were no any statistical signiﬁcant lon-
gitudinal FA changes.
Regarding the relationship of change in GM MD and clinical scales,
surprisingly at the whole brain, hemispheric, and lobar level, all areas
showed an inverse relationship between delta Barthel and delta MD
over two months—as Barthel decreased/worsened, MD increased
(Supplemental Table 1). At the VOI level, 15 of 80 VOIs also reached sta-
tistical signiﬁcance with FDR showing an inverse relationship between
delta Barthel and delta MD (Fig. 2 and Supplemental Table 1). No corre-
lations were found between delta MD and delta MMSE or NPI at VOI,
lobar, hemisphere or whole brain cortical or subcortical GM level
(data not shown).3.3. MD as function of Barthel score in cross-sectional and longitudinal
analyses
The relationship between Barthel score and both MD values
(Figs. 3A–B: cross-sectional) andMD changes (Figs. 3C–D: longitudinal)
seems to follow a quadric ﬁt within a window of Barthel 100 to approx-
imately 70.Within thiswindow,MDvalues seem to follow two different
phases: Phase 1. MD follows a decrease (possibly linear) towards or
beyond z-score=−2; Phase 2.MD is still reduced but tends to increase
towards the normal range (Figs. 3A and C). A third phase exists within a
window of Barthel ~70 and below, inwhichMD is increasing butwithin
the normal to low normal range and with a lower rate of change
(Figs. 3A and C). MD values seem to have the same tendency across all
brain lobes (Figs. 3B and D). In summary, it seems that MD tends to
decrease in earlier stages of disease (Barthel 100 to ~85), then begins
to increase rapidly and later more slowly towards normal or lower nor-
mal values starting from approximately Barthel 85 and below.3.4. Thickness as function of Barthel score in cross-sectional and longitudinal
analyses
When exploring the relationship between Barthel score and both
cross-sectional measurements of cortical thickness/volume as well as
the longitudinal changes in these values with splines, no clear pattern
emerged. There was no discernible relationship between modiﬁed
Barthel and thickness/volume and there was no change in thickness
over two months (not shown).4. Discussion
To our knowledge, this is the ﬁrst study with complete cortical and
subcortical GM quantiﬁcation of MD both cross-sectionally and longitu-
dinally in a cohort of sCJD subjects. In our cross-sectional analysis,
decreased MD (restricted diffusion) was seen mostly in the temporal
and parietal lobes and subcortical VOIs; no VOIs had increased MD.
Our longitudinal analysis surprisingly showed that there was a
signiﬁcant inverse correlation between Barthel and MD, as Barthel
decreased or worsened, MD increased. Furthermore, using splines, we
found a nonlinear relationship between either MD or change in MD
and baseline Barthel score (an indication of the patient's clinical
stage) (Fig. 3). This suggest a more complex – neither linear, nor
unidirectional – model of MD changes over the disease course. The
well-established and documented phase of decreased MD appears to
be followed by a stage of increasing MD that is highly correlated with
worsening of clinical function.
Table 2
Cross-sectional analysis of average gray matter mean diffusivity in sCJD compared to controls by whole brain and volumes of interest after correction for multiple comparisons.
Whole brain Mean diffusivitya (mm2/s × 10−3)
Controls sCJD
Cortical GM 1041 ± 91 945 ± 88***
Subcortical GM 913 ± 75 830 ± 56***
VOIs Mean diffusivitya (mm2/s × 10−3)
Left hemisphere Right hemisphere
Controls sCJD Controls sCJD
Frontal
Caudalmiddlefrontal 1070 ± 109 985 ± 111 1057 ± 136 949 ± 113(*)
Lateralorbitofrontal 1003 ± 96 946 ± 85 984 ± 77 908 ± 99(*)
Medialorbitofrontal 1057 ± 77 981 ± 112 1064 ± 97 960 ± 112**
Parsopercularis 1137 ± 127 1064 ± 104 1097 ± 135 1013 ± 136
Paracentral 971 ± 139 891 ± 100 968 ± 108 918 ± 99
Parsorbitalis 1092 ± 134 1055 ± 168 1023 ± 85 949 ± 160
Parstriangularis 1134 ± 169 1089 ± 143 1074 ± 111 1005 ± 168
Precentral 1113 ± 126 1029 ± 91(*) 1092 ± 115 1016 ± 113
Rostralmiddlefrontal 1160 ± 136 1059 ± 141 1143 ± 149 1022 ± 155
Superiorfrontal 1075 ± 88 994 ± 105(*) 1060 ± 111 961 ± 101(*)
Frontalpole 1150 ± 139 1059 ± 229 1147 ± 147 1054 ± 259
Limbic
Caudalanteriorcingulate 1078 ± 124 1006 ± 114 1048 ± 114 969 ± 111
Isthmuscingulate 950 ± 86 835 ± 109** 972 ± 104 823 ± 92**
Posteriorcingulate 951 ± 86 887 ± 92 974 ± 117 857 ± 103**
Rostralanteriorcingulate 1023 ± 71 953 ± 98(*) 1005 ± 77 927 ± 109(*)
Insula 1061 ± 105 988 ± 104 1089 ± 103 993 ± 110(*)
Temporal
Entorhinal 952 ± 63 920 ± 127 987 ± 89 935 ± 182
Fusiform 912 ± 78 796 ± 107** 889 ± 59 783 ± 126**
Inferiortemporal 925 ± 101 801 ± 97*** 917 ± 103 763 ± 107***
Middletemporal 990 ± 104 861 ± 103*** 978 ± 104 821 ± 120***
Temporalpole 1095 ± 184 1035 ± 107 1026 ± 89 1053 ± 197
Parahippocampal 1041 ± 67 909 ± 114** 1011 ± 65 872 ± 129**
Superiortemporal 1085 ± 104 1017 ± 127 1063 ± 107 989 ± 129
Transversetemporal 1123 ± 168 1065 ± 129 1101 ± 144 1079 ± 151
Bankssts 1015 ± 112 858 ± 118** 974 ± 105 838 ± 130**
Parietal
Inferiorparietal 1038 ± 129 873 ± 127** 1009 ± 101 845 ± 136**
Postcentral 1153 ± 147 1033 ± 103** 1123 ± 136 1038 ± 114(*)
Precuneus 990 ± 101 840 ± 112** 1005 ± 81 851 ± 121**
Superiorparietal 1084 ± 126 949 ± 126** 1086 ± 116 960 ± 149(*)
Supramarginal 1084 ± 135 931 ± 129** 1051 ± 118 909 ± 132**
Occipital
Cuneus 1051 ± 84 936 ± 109** 1057 ± 74 940 ± 149(*)
Lateraloccipital 977 ± 101 874 ± 123(*) 973 ± 103 839 ± 133**
Lingual 983 ± 92 915 ± 146 1017 ± 95 916 ± 132(*)
Pericalcarine 1089 ± 130 990 ± 107** 1094 ± 136 963 ± 132**
Subcortical GM
Amygdala 933 ± 61 858 ± 65** 931 ± 77 878 ± 66(*)
Caudate 925 ± 87 822 ± 92** 952 ± 110 834 ± 101**
Hippocampus 1107 ± 96 1047 ± 81 1083 ± 106 1032 ± 81
Pallidum 813 ± 76 722 ± 67** 796 ± 82 718 ± 59**
Putamen 807 ± 79 719 ± 69** 810 ± 75 705 ± 73**
Thalamus 896 ± 82 815 ± 63** 901 ± 79 814 ± 65**
Bold are statistically signiﬁcant results of decreasedMD between sCJD and controls. *** = areas with statistically signiﬁcant reducedMD in sCJD compared to controls (0.001≤ p b 0.01).
** = areas with statistically signiﬁcant reduced MD in sCJD compared to controls (0.01 ≤ p b 0.05); (*) = areas with trend of statistically signiﬁcant reduced MD in sCJD compared to
controls (0.05 ≤ p value b 0.1). No VOI had increased MD in sCJD compared to controls. GM= gray matter.
a Meandiffusivity values forwhole brain cortical and subcortical graymatter and for singleVOIs are reported inmm2/s × 10−3 as average± standarddeviation for both control and sCJD
groups.
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Our results conﬁrmprior non-quantitative assessments showingdif-
fuse involvement of the GM in sCJD (Shiga et al., 2004; Tschampa et al.,
2007; Vitali et al., 2011; Zerr et al., 2009). The pattern of involvement
showed a relative increasing anterior to posterior gradient of restricted
MD in the cortical GM, with less involvement of frontal andmost limbic
regions compared to temporal, parietal, posterior cingulate and to a
lesser extent, occipital regions. Furthermore, all subcortical regions,except for the hippocampi, and right amygdala, had reduced MD after
FDR.
4.2. Regional involvement and discordance between visual and quantiﬁed
assessment
Whereas some visual assessment studies in sCJD have shown exten-
sive frontal cortical involvement (Tschampa et al., 2007; Vitali et al.,
2011; Young et al., 2005; Zerr et al., 2009), particularly in the superior
Fig. 1. Averagemean diffusivity (MD) cross-sectionally in sCJD cohort versus controls per brain volumes of interest (VOIs) (after correction for multiple comparisons (FDR)). The colored
areas are regionswith signiﬁcantly reduced (or a strong trend towards)meanMD in sCJD versus controls superposed on theMontreal Neurological Institute (MNI) atlas.WhiteVOIs have a
trend towards reduced average mean MD with p-values ≥0.05 and b0.1. Teal VOIs have signiﬁcantly reduced average MD with p values ≥0.01 and b0.05. Blue VOIs have signiﬁcantly
reduced average MD with p values ≥0.001 and b0.01. Sporadic CJD had VOIs with reduced average MD compared to controls primarily in temporal and parietal lobes and deep nuclei.
No VOI had increased MD in sCJD compared to controls. Orientation is radiologic (right brain is left side of image).
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2005), we only found a trend towards frontal cortical involvement
(Fig. 1). Zerr et al. found on visual assessment that many non-CJDFig. 2. Inverse correlation of change in Barthel and change in MD over twomonths. Distribution
MD over twomonths for all cortical VOIs. The graph shows the number of cortical VOIs (y axis)
dotted line shows the limit for statistically signiﬁcant values without FDR; the red dash line sho
and theVOI level, all areas (except the right parahippocampus) showed an inverse (negative) re
average MD with 15 VOIs (13 cortical and 2 subcortical; outside red dotted line) reaching st
increased. For many brain VOIs, there was at least a trend towards increased MD with worsencontrols had frontal cortical hyperintensities that were misread as con-
sistent with CJD and thus frontal regions could not reliably distinguish
sCJD from controls (Zerr et al., 2009). The relative lack of frontal andof Spearman Rank Correlation Coefﬁcients of change in themodiﬁed Barthel and average
per each Spearman Rank Correlation Coefﬁcient (x axis: values from 1 to−1). The green
ws the limit for statistically signiﬁcant values with FDR. At whole brain, hemispheric, lobar
lationship between the change in the (delta)modiﬁed Barthel and the change in the (delta)
atistical signiﬁcance with FDR (p b 0.05)—as modiﬁed Barthel decreased/worsened, MD
ing modiﬁed Barthel.
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sectional analysis is in contrast to our, and others', clinical experience,
in which there was clear involvement on DWI and ADC sequences in
these regions (Tschampa et al., 2007; Vitali et al., 2011; Young et al.,
2005). We discuss below why this might be the case.
We partly conﬁrm sparing of the peri-Rolandic cortex noted previ-
ously (Lin et al., 2006; Young et al., 2005); here we found, on average,
sparing of primarymotor andmuch of the right primary somatosensory
cortices, but involvement of the left post-central gyrus. Lin et al.
suggested that this relative sparing of the Rolandic cortex by visual
assessment might be due to concurrent iron-related hypointensity
(so called T2 black-out effect) (Lin et al., 2006). Our data, however,
suggested against this because quantitative MD assessment should
overcome the possible T2 black-out effect (as there is no evidence that
iron content affects diffusivity) and we found relative sparing of this
region (Supplemental data). Therefore, other factors are necessary to
explain the relative sparing of this area on DWI.
Although the cingulate and insula are usually bright on visual assess-
ment in sCJD (Tschampa et al., 2007; Vitali et al., 2011), on our quanti-
tative assessment these regions generally only trended towards
signiﬁcant involvement; only the isthmus cingulate and right posterior
cingulate survived FDR. The cingulate and insula are known to be areas
of DWI/FLAIR hyperintensity even in healthy subjects (Asao et al.,Fig. 3. Cross-sectional and longitudinal (change) in Mean Diffusivity in sCJD vs. Barthel score.
(A) whole brain and (B) at lobar/region level (frontal, limbic, temporal, parietal, occipital, deep
in the ﬁgures represent average of MD values within each lobe/region for each subject studied
interval (black solid lines) and estimate of average tendency in MD (red dotted line). In B, w
Longitudinal data. The average change over 2 months in MD in seven sCJD subjects in (C) wh
occipital, deep nuclei) as a function of baseline Barthel score was estimated using splines. In C,
in change of MD (red dotted line). In D, we show estimates of average tendency in change of M
excluding 7 patients with longitudinal scans (not shown). Deep nuclei = thalamus, pallidum,2008), however, which might lead to false-positive readings in non-
CJD and false-negatives in sCJD (Zerr et al., 2009). Using the ADC map
should help identify true abnormalities in these regions (Asao et al.,
2008; Vitali et al., 2011). Mesial-temporal involvement often also is
difﬁcult to interpret on DWI due to artifact (Tschampa et al., 2007;
Zerr et al., 2009). In a prior, visual assessment study, we read the hippo-
campus/amygdala as one structure and reported involvement (Vitali
et al., 2011), whereas here quantitatively we found involvement of the
amygdala, but not the hippocampus.
Corroborating several prior visual assessment papers, we found
relatively extensive subcortical involvement and partial occipital
involvement (Tschampa et al., 2007; Vitali et al., 2011; Young et al.,
2005). A recent paper focusing on the role of MRI, CSF and EEG in the
diagnosis of sCJD versus healthy controls and non-prion rapidly pro-
gressive dementias examined quantitatively 10 mm spherical ROIs in
gray (precuneus, frontal cortex, pulvinar and caudate head) and white
(posterior limb of the internal capsule and corpus callosum) matter
regions of nine sCJD subjects and found decreased MD in the caudate
and pulvinar ROIs, and no FA abnormalities (Wang et al., 2013). Despite
it being a more limited study in terms of regions analyzed and the
number of subjects, it partially supports our cross-sectional ﬁndings,
although we found more extensive reduced MD. Similarly to Wang
et al., we conﬁrm in a more neuroanatomically extensive analysis the(A–B) Cross-sectional data. Using splines, we estimated group-wise average MD values at
nuclei), as a function of baseline modiﬁed Barthel scores for the 26 sCJD subjects. Circles
either cross-sectionally (A–B) or longitudinally (C–D). In A, we show the 95% conﬁdence
e show estimates of average tendency in MD at lobar levels (colored solid lines). (C–D)
ole brain and (D) in each lobes/region independently (frontal, limbic, temporal, parietal,
we show the 95% conﬁdence interval (black solid lines) and estimate of average tendency
D at the lobar level (colored solid lines). We obtained an identical graph to Fig. 3A even by
caudate and putamen; limbic lobe = cingulate cortex and insula.
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sCJD compared to controls.
Involvement of the GP is uncommonly reported in sCJD on MRI
(Shiga et al., 2004; Tschampa et al., 2007; Vitali et al., 2011; Young
et al., 2005). In our prior visual assessment, we often found decreased
ADC in the GP often without concomitant DWI hyperintensity (Vitali
et al., 2011). In this current analysis, quantitatively we found restricted
MD in bilateral GP, supporting our previous ADC ﬁnding. The relative
lack of GP involvement on DWI/FLAIR might be from the high iron
deposition in the GP causing a T2 black-out effect on visual assessment
(Lin et al., 2006; Schenker et al., 1993; Vitali et al., 2011).
Contrary to previous observations of T1 hyperintensity in certain
deep nuclei structures, particularly the GP (de Priester et al., 1999;
Vitali et al., 2011), in this study, T1 relaxometry did not show any differ-
ences between our sCJD cohort and controls in any regions, including
the GP. This might be because T1 hyperintensity has only been reported
in a few sCJD patients and our study was at group-wise level.
4.3. Comparison of mean MD on a lobar level across sCJD based on prion
type or codon 129 polymorphism
MRI pattern differences within sCJD molecular subtypes (based on
both prion typing and codon 129 polymorphism) (Parchi et al., 1999)
described by Meissner et al. (Meissner et al., 2009) require updating
for several reasons. Qualitatively assessment of real pattern of involve-
ment in sCJD is problematic, especially when using different scanners
and MRI sequences. Moreover, sCJD subtype classiﬁcation has evolved
due to many cases with concomitant presence of prion types 1 and 2
(Polymenidou et al., 2005; Puoti et al., 2012). Finally, the pattern of
involvement likely evolves in the course of the disease (see Section “4.5
MD changes over time” below). Due to the small number of patients in
this study, it was not possible for us to compare all sCJD molecular sub-
types. Nevertheless, our regression analysis based on either prion type
or codon 129 polymorphism (correcting for disease stage based on
Barthel) showed differences based on these two factors. Subjects with
type 1 prions had more reduced cortical average MD than those with
type 2 prions in several lobes bilaterally. Furthermore, codon 129 VV
cases showed more reduced MD in the deep nuclei compared to MM
cases. These ﬁndings need to be explored in a larger cohort.
4.4. Atrophy and MD
No cortical or subcortical regions showed any atrophy relative to
controls. Clinically, on serial visual assessment, however, we note signif-
icant atrophy in sCJD patients with prolonged survival, typically a
year or longer, but often after just several months. Atrophy might not
have been detected in this analysis for several reasons, including
group-wise averaging might have prevented detection of atrophy,
Freesurfer might not have been sufﬁciently sensitive particularly with
1.5 T scans, and/or atrophymight occur at later stages of disease. Larger
serial studies, on stronger magnets, such as 3 T, might be required to
determine the extent and rate of atrophy in sCJD. Not surprisingly, we
also found no correlation of MD with either thickness/volume. This
might also be because reduced MD in prion disease is associated with
vacuolation, prion deposition and possibly gliosis (Geschwind et al.,
2009; Manners et al., 2009). Atrophy, however, is characterized by
increased MD values (Chua et al., 2009; Whitwell et al., 2010).
4.5. MD changes over time
Our longitudinal group-wise analysis suggested increasing MD in
most brain regions over twomonths, with only a few regions suggesting
slightly reducing diffusion. Moreover, there was a strong inverse corre-
lation between the change in clinical function (modiﬁed Barthel index)
and MD—as clinical function worsened, MD increased (Fig. 2 and
Supplemental Table 1). Although restricted MD is a well documentedﬁnding and strong diagnostic marker for sCJD (Shiga et al., 2004; Vitali
et al., 2011; Zerr et al., 2009), surprisingly our data suggests that in
the course of the disease this MD change is not unidirectional, decreas-
ing early and later becoming less reduced.
This ﬁnding, however, might be consistent with some prior ﬁndings
in human prion disease. Hyare et al. found that in genetic prion disease,
increasing whole GMmeanMDwas an independent predictor of wors-
ening CDR, Barthel and Rankin scales (Hyare et al., 2010). Our ﬁndings
also are consistent with literature showing that regions with initially
restricted diffusion might show disappearance of this restricted diffu-
sion, consistent with increasing MD, particularly in patients with
prolonged prion disease (Hirose et al., 1998; Matoba et al., 2001;
Tschampa et al., 2003; Ukisu et al., 2005). Therefore, decreasing MD in
sCJD in earlier affected regions might arrest and possibly reverse with
progressive increasingMD towards normalization (“relative normaliza-
tion”) and even increased MD (Fig. 3) (Fulbright et al., 2006; Haik et al.,
2008; Hirose et al., 1998). Importantly for consideration of future treat-
ment trials, our data suggests that the increasingMDphase is associated
with the more dramatic loss of function (Fig. 3) and might represent a
late, and possibly even irreversible, phase of disease.
As noted previously, different stages of disease are probably
co-occurring in the same brain (Haik et al., 2008; Hirose et al., 1998).
Because many of our cases in this analysis were not very early stage,
we suspect less involvement of frontal and limbic regions in this
cross-sectional analysis is due to these frontal/limbic regions having
been affected earlier in the disease course and might have already
gone through the phase of decreasingMD and be at the stage of increas-
ing or “relative normalization of”MD.
The relative normalization of MD in the middle to late stages of the
disease might be due to underlying histopathological changes. The
later stages of sCJD are characterized by neuronal loss and gliosis
(Kretzschmar et al., 1996; Ukisu et al., 2005). Severe brain atrophy in
late stage CJD correlates with the disappearance of previous hyperin-
tense DWI signal, (Hirose et al., 1998; Matoba et al., 2001; Tribl et al.,
2002), probably due to increasing MD values. Therefore, neuronal loss
and/or gliosis might allow increased water ﬂow and augmentation of
MD values in regions in late disease stages (Tschampa et al., 2003).
This is consistent with increased MD seen in other neurodegenerative
diseases, (Chua et al., 2009; Kantarci et al., 2010; Oreja-Guevara et al.,
2005; Whitwell et al., 2010) as well as genetic prion disease (Cohen
et al., 2009), which probably due to progression of neuronal loss
(and/or gliosis). Interestingly, in a single case of fatal familial insomnia,
withMRI four days prior to death, increasedMD values appeared to cor-
relate with gliosis but not PrPSc deposition (Haik et al., 2008). It is not
clear why gliosis might cause increased MD; some literature suggests
otherwise (Pfefferbaum et al., 2010), and we could predict that isolated
gliosis (not associatedwith neuronal loss) would cause a reduced diffu-
sion of water molecules by adding a barrier. Furthermore, as gliosis and
neuronal loss often are highly correlated in prion disease (Manners
et al., 2009), and many studies assess gliosis neuropathologically with-
out accounting for neuronal loss, it might be that increased MD actually
is due to neuronal loss, not gliosis. Additionally, the increased size
of vacuoles and their coalescence in late stage of CJD also might be
expected to cause an increased diffusion of free water molecules
(Geschwind et al., 2009).4.6. Clinical correlation with MRI metrics
The lack of correlation between clinical scales (Barthel, NPI, and
MMSE) and gray matter MRI values cross-sectionally might be due to
several reasons. As we did not ﬁnd a signiﬁcant difference in thick-
ness/volume in our groupwise analysis of sCJD versus controls, there
might have not been sufﬁcient atrophy in individual subjects to corre-
late with clinical scales. In sCJD, there is often not appreciable atrophy
except in late stages of patients with prolonged disease courses.
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non-linear and non-unidirectional (i.e., J-shaped curve) it makes sense
that these scales that are unidirectional and generally linear in this dis-
ease might not correlate with MD cross-sectionally or longitudinally.
The individual variability in clinical phenotype of sCJD patients would
likely result in great variations in the NPI andMMSE, further explaining
the lack of correlation of these measures with MD. As noted in the
Results section, however, we found that the Barthel correlatedwith lon-
gitudinal MD changes in several brain regions. This is not unexpected as
we and others have found that ADL scales, such as the Barthel, track CJD
progression far better than neuropsychometric measures (Geschwind
et al., 2013;Mead et al., 2011). Contrary towhatwe had expected, how-
ever, the correlation between Barthel and MD changes was inverse, as
Barthel was decreasing, MD tends to increase. Our longitudinal data
seems to suggest that a steeper decline in function (i.e., Barthel) occurs
at a middle-late stage of disease, once the MD values start to increase
towards a relative normalization of values (Fig. 3). This ﬁnding needs
to be studied in a larger cohort.
5. Conclusion
Our ﬁndings show that MRI is not only important for sCJD diagnosis,
but also for studying the underlying pathophysiology of prion disease.
This study provides insight into the evolution of MRI changes in sCJD,
suggesting amodel for pathological progression of humanprion disease.
If our hypothesis of later stage normalization of MD is correct, it would
be difﬁcult to use MD values in isolation to monitor sCJD progression in
future treatment trials, as onemight not know atwhich point on a U or J
shaped curve the region is moving towards decreasing versus increas-
ing MD. Serial MD values, however, might inform whether the MD
values are decreasing or increasing. Additionally, inclusion of other
MRI ﬁndings, such as T2-quantiﬁcation or atrophy, might help deter-
mine a patient's disease stage. Lastly, the recent evidence for a prion-
like spread for other neurodegenerative dementias (Prusiner, 2012;
Raj et al., 2012) has highlighted the need for better understanding dis-
ease spread in sCJD. Larger longitudinal studies are needed to conﬁrm
our model of MD changes over the course of the disease.
One limitation of this study was that the limited number of controls
made it not possible to obtain normal threshold values to assess diffu-
sion changes at single subject levels. Future studies applying similar
methodologies at a single subject level might be able to show better
the correlation between diffusion changes and atrophy, as well as possi-
ble differences in between the different sCJD molecular subtypes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2014.01.011.
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